[{"id":"ddf0452e-32bb-460c-8ff8-6fa35814d73e","acronym":"GNC-035-103","url":"https://clinicaltrials.gov/study/NCT05160545","created_at":"2021-12-16T13:53:38.176Z","updated_at":"2024-07-02T16:35:21.629Z","phase":"Phase 1","brief_title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05160545 - GNC-035-103","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nebratamig (GNC-035)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/26/2021","start_date":" 11/26/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-01-31"},{"id":"ca421334-f9eb-4377-938c-37226f3e8745","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039931","created_at":"2021-09-10T16:57:17.104Z","updated_at":"2024-07-02T16:35:53.134Z","phase":"Phase 1","brief_title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05039931","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nebratamig (GNC-035)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2023-03-16"}]